Piclidenoson (CF101)
Moderate-to-Severe Plaque Psoriasis
Key Facts
About Can Fite Biopharma
Can Fite Biopharma focuses on the discovery and clinical development of platform-based therapeutics that engage the A3 adenosine receptor, a target highly expressed in inflammatory and cancer cells. Its most advanced programs, Piclidenoson and Namodenoson, are in Phase 3 and Phase 2b trials, respectively, for major autoimmune diseases and liver cancer. The company's strategy involves advancing its clinical pipeline through partnerships and its public listing, aiming to bring novel, orally administered treatments to market.
View full company profileAbout Can Fite Biopharma
Can Fite Biopharma focuses on the discovery and clinical development of platform-based therapeutics that engage the A3 adenosine receptor, a target highly expressed in inflammatory and cancer cells. Its most advanced programs, Piclidenoson and Namodenoson, are in Phase 3 and Phase 2b trials, respectively, for major autoimmune diseases and liver cancer. The company's strategy involves advancing its clinical pipeline through partnerships and its public listing, aiming to bring novel, orally administered treatments to market.
View full company profileTherapeutic Areas
Other Moderate-to-Severe Plaque Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| Envudeucitinib | Alumis | Phase 3 |